Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOTRICITY INC.BTCY · Entity 8507 | Chief Financial Officer | October 26, 2017 | March 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOTRICITY INC.
Report date October 26, 2017 · Filed March 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2030-12-31 | Direct | 50,000 |
Reported balance
After 2017-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-26 · Grant · Acquired 50,000 · Balance 50,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2030-12-31 | Direct | 100,000 |
Reported balance
After 2018-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-31 · Grant · Acquired 50,000 · Balance 100,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2030-12-31 | Direct | 150,000 |
Reported balance
After 2018-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-30 · Grant · Acquired 50,000 · Balance 150,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2030-12-31 | Direct | 200,000 |
Reported balance
After 2018-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-09-30 · Grant · Acquired 50,000 · Balance 200,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2028-12-30 | Direct | 250,000 |
Reported balance
After 2018-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-31 · Grant · Acquired 50,000 · Balance 250,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2029-03-30 | Direct | 300,000 |
Reported balance
After 2019-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-31 · Grant · Acquired 50,000 · Balance 300,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-06-29 | Direct | 350,000 |
Reported balance
After 2019-06-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-06-30 · Grant · Acquired 50,000 · Balance 350,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2029-09-29 | Direct | 400,000 |
Reported balance
After 2019-09-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-09-30 · Grant · Acquired 50,000 · Balance 400,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2029-12-30 | Direct | 450,000 |
Reported balance
After 2019-12-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-31 · Grant · Acquired 50,000 · Balance 450,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2030-03-31 | Direct | 500,000 |
Reported balance
After 2020-03-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-03-31 · Grant · Acquired 50,000 · Balance 500,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2030-06-30 | Direct | 550,000 |
Reported balance
After 2020-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-06-30 · Grant · Acquired 50,000 · Balance 550,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2030-09-30 | Direct | 600,000 |
Reported balance
After 2020-09-30 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-09-30 · Grant · Acquired 50,000 · Balance 600,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-01-23 | Direct | 650,000 |
Reported balance
After 2020-01-24 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-01-24 · Grant · Acquired 50,000 · Balance 650,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2030-12-31 | Direct | 700,000 |
Reported balance
After 2020-12-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-12-31 · Grant · Acquired 50,000 · Balance 700,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2031-03-31 | Direct | 750,000 |
Reported balance
After 2021-03-31 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-03-31 · Grant · Acquired 50,000 · Balance 750,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2031-06-30 | Direct | 800,000 |
Reported balance
After 2021-06-30 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-06-30 · Grant · Acquired 50,000 · Balance 800,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2031-09-30 | Direct | 850,000 |
Reported balance
After 2021-09-30 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-09-30 · Grant · Acquired 50,000 · Balance 850,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2031-12-31 | Direct | 900,000 |
Reported balance
After 2021-12-31 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-12-31 · Grant · Acquired 50,000 · Balance 900,000 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2032-03-31 | Direct | 937,594 |
Reported balance
After 2022-03-31 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2022-03-31 · Grant · Acquired 37,594 · Balance 937,594 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2032-06-30 | Direct | 991,421 |
Reported balance
After 2022-06-30 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2022-06-30 · Grant · Acquired 53,827 · Balance 991,421 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2032-09-30 | Direct | 1,109,703 |
Reported balance
After 2022-09-30 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2022-09-30 · Grant · Acquired 118,282 · Balance 1,109,703 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2032-12-30 | Direct | 1,328,488 |
Reported balance
After 2022-12-31 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2022-12-31 · Grant · Acquired 218,785 · Balance 1,328,488 F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2022 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 218,785 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 22 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,328,488 Underlying: Common Stock · 218,785 shares Expires 2032-12-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| September 30, 2022 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 118,282 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 21 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,109,703 Underlying: Common Stock · 118,282 shares Expires 2032-09-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| June 30, 2022 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 53,827 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 20 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,421 Underlying: Common Stock · 53,827 shares Expires 2032-06-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| March 31, 2022 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 37,594 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 19 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937,594 Underlying: Common Stock · 37,594 shares Expires 2032-03-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| December 31, 2021 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 18 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| September 30, 2021 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 17 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 50,000 shares Expires 2031-09-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| June 30, 2021 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 16 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| March 31, 2021 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 15 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| December 31, 2020 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 14 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| September 30, 2020 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 12 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 50,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| June 30, 2020 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 11 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| March 31, 2020 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 10 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| January 24, 2020 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 13 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 50,000 shares Expires 2030-01-23 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| December 31, 2019 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 9 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| September 30, 2019 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 8 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 50,000 shares Expires 2029-09-29 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| June 30, 2019 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 7 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-29 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| March 31, 2019 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 6 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| December 31, 2018 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 5 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2028-12-30 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| September 30, 2018 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 4 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| June 30, 2018 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 3 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| March 31, 2018 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 2 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
| October 26, 2017 Filed Mar 13, 2023 20:10 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantWarrants · Derivative | 50,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-23-007404 · ownership.xml · derivative · entry 1 Ayanoglou John · CIK 0001783723 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The Warrants were issued to the Reporting Person as a consideration for his services to the Issuer and are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.